Back to top
more

Bristol Myers Squibb (BMY)

(Delayed Data from NYSE)

$47.81 USD

47.81
9,409,499

-0.04 (-0.08%)

Updated Aug 14, 2025 04:00 PM ET

After-Market: $47.86 +0.05 (0.10%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (146 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks News

New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..

Zacks Equity Research

Biotech Stock Roundup: AGEN, SRPT Surge & BIIB, REGN Provide Pipeline Updates

The biotech sector was in focus last week with pipeline and regulatory updates from Agenus (AGEN) and Sarepta (SRPT), among others.

Zacks Equity Research

Bristol-Myers (BMY) Teams Up With Agenus for Antibody Program

Bristol-Myers (BMY) obtains exclusive license for Agenus' antibody program, AGEN1777, for an upfront payment of $200 million and up to $1.36 billion in milestone payments.

Zacks Equity Research

Company News for May 19, 2021

Companies In The News Are: WMT, TWLO, WFC, BRK.B, BMY, AGEN

Zacks Equity Research

Agenus (AGEN) Soars on Global License Deal With Bristol-Myers

Agenus (AGEN) inks a definitive agreement with Bristol-Myers, wherein it will grant license to its bispecific antibody program AGEN1777 and another undisclosed target, to the latter.

Zacks Equity Research

Bristol Myers (BMY) Announces New Data on Cardiovascular Candidate

Bristol Myers (BMY) announces new positive data on mavacamten from a late-stage study at the American College of Cardiology's 70th Annual Scientific Session.

Zacks Equity Research

Corcept's (CORT) Lead Drug Korlym Aids Growth Amid Competition

Corcept's (CORT) Cushing's syndrome drug, Korlym, is making good progress. Other pipeline candidates are advancing as well. However, sole dependence on Korlym for growth remains an overhang.

Zacks Equity Research

Prothena (PRTA) Q1 Loss Wider Than Expected, Pipeline in Focus

Prothena (PRTA) reports a wider loss in the first quarter of 2021. The pipeline remains in focus with the planned initiation of three late-stage studies for birtamimab, prasinezumab and PRX004.

Zacks Equity Research

Halozyme (HALO) Stock Down Despite Q1 Earnings & Sales Beat

Halozyme (HALO) first-quarter earnings and sales beat estimates. The company retains 2021 guidance.

Zacks Equity Research

Bristol Myers Squibb (BMY) Gains As Market Dips: What You Should Know

In the latest trading session, Bristol Myers Squibb (BMY) closed at $64.70, marking a +0.4% move from the previous day.

Zacks Equity Research

ImmunoGen (IMGN) Q1 Earnings Top, Pivotal Studies Delayed

ImmunoGen (IMGN) reports narrower-than-expected loss but misses revenue estimates. Meanwhile, data readouts from pivotal studies on lead candidate get delayed due to COVID-19. Stock down.

Zacks Equity Research

Exelixis (EXEL) Q1 Earnings Miss Estimates, Revenues Beat

Exelixis (EXEL) missed on earnings in the first quarter but beats on revenues.

Zacks Equity Research

Corcept's (CORT) Q1 Earnings Miss Estimates, Revenues Fall Y/Y

Corcept (CORT) reports wider-than-expected loss in the first quarter of 2021, with its revenues also missing estimates.

Zacks Equity Research

Iovance (IOVA) Q1 Earnings Miss Estimates, Pipeline in Focus

Iovance's (IOVA) first-quarter earnings lag estimates. The company is progressing well in terms of development of its lead pipeline candidate.

Zacks Equity Research

Epizyme's (EPZM) Q1 Earnings Miss, Revenues Beat Estimates

Epizyme (EPZM) reports wider-than-expected loss in the first quarter of 2021 despite its revenues beating estimates.

Zacks Equity Research

FATE Reports Wider-Than-Expected Q1 Loss, Beats on Revenues

FATE reports a wider Q1 loss on increased R&D expenses.

Zacks Equity Research

bluebird (BLUE) Q1 Loss Wider Than Expected, Revenues Beat

bluebird (BLUE) reports a wider-than-expected loss for the first quarter of 2021 while revenues beat estimates.

Zacks Equity Research

Clovis (CLVS) Q1 Earnings Beat, COVID-19 Hurts Rubraca Sales

Clovis (CLVS) reports lower-than-expected loss for first-quarter 2021. Lower new patient start amid COVID-19 hurts U.S. sales of Rubraca. Stock up.

Zacks Equity Research

Editas (EDIT) Q1 Earnings Miss Estimates, Revenues Beat

Editas (EDIT) reports wider-than-expected loss in the first quarter of 2021 while revenues beat estimates. Pipeline development remains in focus for the company.

Zacks Equity Research

Pfizer (PFE) Q1 Earnings Beat, COVID-19 Vaccine Boosts Sales

Pfizer (PFE) beats estimates for earnings and sales in the first quarter. It lifts its financial outlook for 2021. Stock up.

Zacks Equity Research

Pfizer's (PFE) Key Drugs Likely to Drive Its Q1 Earnings

Higher sales of Pfizer's (PFE) key brands, Eliquis, Ibrance and Inlyta, and revenues from COVID-19 vaccine are likely to have driven sales in the first quarter.

Zacks Equity Research

Agios' (AGIO) Q1 Earnings Miss, Pipeline Makes Progress

Agios (AGIO) incurs wider-than-expected loss in the first quarter of 2021. The company fails to record revenues due to the sale of its oncology portfolio including Tibsovo.

Kinjel Shah headshot

Merck (MRK) Q1 Earnings & Sales Miss, COVID-19 Hurts Vaccines

Merck (MRK) misses Q1 estimates for earnings and sales. Stock down in pre-market.

Zacks Equity Research

Bristol-Myers (BMY) Misses on Q1 Earnings, Opdivo Sales Decline

Bristol-Myers (BMY) misses earnings and sales estimates in the first quarter on weak Opdivo sales.

Zacks Equity Research

Bristol Myers Squibb (BMY) Q1 Earnings and Revenues Miss Estimates

Bristol Myers (BMY) delivered earnings and revenue surprises of -3.33% and -0.36%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here is Why Growth Investors Should Buy Bristol Myers (BMY) Now

Bristol Myers (BMY) is well positioned to outperform the market, as it exhibits above-average growth in financials.